MVA as a vector for vaccines against HIV-1

Expert Review of Vaccines

Volumn 3, Issue 4 SUPPL., 2004, Pages

  Im, Eung Jun ^a   Hanke, Tomáš ^a  

^a UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

HIV 1 vaccines; MVA; Prime boost

Indexed keywords

CD4 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; NEF PROTEIN; VIRUS VECTOR;

BLISTER; CLINICAL TRIAL; ERYTHEMA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNIZATION; IMMUNOMODULATION; NONHUMAN; PRIORITY JOURNAL; RECOMBINANT DNA TECHNOLOGY; REVIEW; T LYMPHOCYTE; VACCINE PRODUCTION; VACCINIA VIRUS;

AIDS VACCINES; ANIMALS; CLINICAL TRIALS; HIV-1; HUMANS; VACCINIA VIRUS;

EID: 4344714042     PISSN: 14760584     EISSN: None     Source Type: Journal    
DOI: 10.1586/14760584.3.4.S89     Document Type: Review

References (81)

1. Klausner RD, Fauci AS, Corey L et al. Medicine. The need for a global HIV vaccine enterprise. Science 300, 2036-2039 (2003). A paper describing a strategy for global co-ordination of HIV vaccine development.
2. McMichael A. T-cell responses and viral escape. Cell 93, 673-676 (1998).
3. Kwong PD, Doyle ML, Casper DJ et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 420, 678-682 (2002).
4. Klenerman P, Wu Y, Phillips R. HIV: current opinion in escapology. Curr. Opin. Microbiol. 5, 408-413 (2002).
5. O'Connor DH, Allen TM, Watkins DI. Cytotoxic T-lymphocyte escape monitoring in simian immunodeficiency virus vaccine challenge studies. DNA Cell Biol. 21, 659-664 (2002).
6. + T-lymphocytes. Nature 421, 852-856 (2003). Provides one (of many) explanations for gradual loss of HIV control by cytotoxic T-lymphocytes (CTLs) during progression to AIDS.
7. Sutter G, Staib C. Vaccinia vectors as candidate vaccines: the development of modified vaccinia virus Ankara for antigen delivery. Curr. Drug Targets Infect. Disord. 3, 263-271 (2003).
8. Mayr A, Hochstein-Mintzel V, Stickl H. Abstammung, Eigenschaften und Verwendung des attenuierten Vaccinia-Stammes MVA. Infection 105, 6-14 (1975).
9. Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968. N. Engl. J. Med. 281, 1201-1208 (1969).
10. Fenner F, Anderson DA, Arita I, Jezek Z, Ladnyi ID. Samllpox and its eradication. World Health Organization (1988).
11. Mayr A, Stickl H, Muller HK, Danner K, Singer H. Der Pockenimpfstamm MVA: Marker, genetische Struktur, Erfahrungen mit der parenteralen Schutzimpfung und Verhalten im. abwehrgeschwachten Organismus. Zentralbl. Bakt. Hyg. I. (Abt. Orig. B) 167, 375-390 (1978).
12. Mackett M, Smith GL, Moss B. Vaccinia virus: a selectable eukaryotic cloning and expression vector. Proc. Natl Acad. Sci. USA 79, 7415-7419 (1982). Demonstration that vaccinia viruses can be used as vectors, which can carry and express foreign genes.
13. Meyer H, Sutter G, Mayr A. Mapping of deletions in the genome of the highly attenuated vaccinia virus MVA and their influence on virulence. J. Gen. Virol. 72, 1031-1038 (1991).
14. Antoine G, Scheiflinger F, Dorner F, Falkner FG. The complete genomic sequence of the modified vaccinia Ankara strain: comparison with other orthopoxviruses. Virology 244, 365-396 (1998).
15. Sutter G, Moss B. Nonreplicating vaccinia vector efficiently expresses recombinant genes. Proc. Natl Acad Sci. USA 89, 10847-10851 (1992).
16. Blanchard TJ, Alcami A, Andrea P, Smith GL. Modified vaccinia virus Ankara undergoes limited replication in human cells and lacks several immunomodulatory proteins: implications for use as a human vaccine. J. Gen. Virol. 79, 1159-1167 (1998).
17. Sutter G, Moss B. Novel vaccinia vector derived from the host range restricted and highly attenuated MVA strain of vaccinia virus. Dev. Biol. Stand. 84, 195-200 (1995). Paper pioneering the use of MVA as a vector for passenger genes.
18. Sutter G, Ramsey EA, Rosales R, Moss B. Stable expression of the vaccinia virus K1L gene in rabbit cells complements the host range defect of a vaccinia virus mutant. J. Virol. 68, 4109-4116 (1994). Paper pioneering the use of MVA as a vector for passenger genes.
19. Moss B, Carroll MW, Wyatt LS et al. Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv. Exp. Med. Biol. 397, 7-13 (1996).
20. Hirsch VM, Fuerst TR, Sutter G et al. Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: Effect of prior immunization with a trivalent SIV vaccine in modified vaccinia virus Ankara. J. Virol. 70, 3741-3752 (1996). The first use of rMVAs as vaccines in nonhuman primates.
21. Hanke T, Blanchard TJ, Schneider J et al. Immunogenicities of iv. and im. administrations of MVA-based multi-CTL epitope vaccine for HIV in mice. J. Gen. Virol. 79, 83-90 (1998).
22. Cosma A, Nagaraj R, Buhler S et al. Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine 22, 21-29 (2003). The first trial report of rMVA as a therapeutic HIV vaccine in HIV-infected humans on antiretroviral drugs.
23. Mwau M Cebere I, Sutton J et al. An HIV-1 clade A vaccine in clinical trials: Stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J. Gen. Virol. 85, 911-919 (2004). The first human trial report on a HIV vaccine using rMVA alone and in a prime-boost regimen.
24. McConkey SJ, Reece WH, Moorthy VS. et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nature Med. 9, 729-735 (2003). The first use of rMVA in a prime-boost regimen in humans.
25. Rochlitz C, Figlin R, Squiban P et al. Phase I immunotherapy with a modified vaccinia virus (MVA) expressing human MUC1 as antigen-specific immunotherapy in patients with MUC1-positive advanced cancer. J. Gene Med. 5, 690-699 (2003).
26. Carroll MW, Moss B. Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line. Virology 238, 198-211 (1997).
27. Drexler I, Heller K, Wahren B, Erfle V, Sutter G. Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation but not in various human transformed and primary cells. J. Gen. Virol. 79, 347-352 (1998).
28. Ramirez JC, Gherardi MM, Esteban M. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J. Virol. 74, 923-933 (2000).
29. Hanke T, McMchael AJ, Samuel RS et al. Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya. Vaccine 21, 109-115 (2002).
30. Ramirez JC, Finke D, Esteban M, Kraehenbuhl JP, Acha-Orbea H. Tissue distribution of the Ankara strain of vaccinia virus (MVA) after mucosal or systemic administration. Arch. Virol. 148, 827-839 (2003).
31. Werner GT, Jentzsch U, Metzger E, Simon J. Studies on poxvirus infections in irradiated animals. Arch. Virol. 64, 247-256 (1980).
32. Hanke T, McMichael AJ, Dennis MJ, Powell LAJ, McLoughlin L, Crome SJ. Safety, biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice. Vaccine (Submitted).
33. Stittelaar KJ, Gruters RA, Schutten M et al. Comparison of the efficacy of early versus late viral proteins in vaccination against SIV. Vaccine 20, 2921-2927 (2002).
34. Moorthy VS, McConkey S, Roberts M et al. Safety of DNA and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 21, 2004-2011 (2003).
35. Moorthy VS, Pinder M, Reece WH et al. Safety and immunogenicity of DNA/modified vaccinia virus Ankara malaria vaccination in African adults. J. Infect. Dis. 188, 1239-1244 (2003).
36. Homemann S, Harlin O, Staib C et al. Replication of modified vaccinia virus Ankara in primary chicken embryo fibroblasts requires expression of the interferon resistance gene E3L. J. Virol. 77, 8394-8407 (2003).
37. Thomson MM, Perez-Alvarez L, Najera R. Molecular epidemiology of HIV-1 genetic forms and its significance for vaccine development and therapy. Lancet Infect. Dis. 2, 461-471 (2002).
38. Cao H, Kanki P, Sankale JL et al. Cytotoxic T-lymphocyte cross-reactivity among different human immunodeficiency virus Type 1 clades: implications for vaccine development. J. Virol. 71, 8615-8623 (1997).
39. Ferrari G, Berend C, Ottinger J et al. Replication-defective canarypox (ALVAC) vectors effectively activate antihuman immunodeficiency virus-1 cytotoxic T-lymphocytes present in infected patients: implications for antigen-specific immunotherapy. Blood 90, 2406-2416 (1997).
40. Walker BD, Korber BT. Immune control of HIV: the obstacles of HLA and viral diversity. Nature Immunol. 2, 473-475. (2001).
41. Burrows SR, Rodda SJ, Suhrbier A, Geysen HM, Moss DJ. The specificity of recognition of a cytotoxic T-lymphocyte epitope. Eur. J. Immunol. 22, 191-195 (1992).
42. McMichael AJ, Hanke T. The quest for an AIDS vaccine: is the CD8+ T-cell approach feasible? Nature Rev. Immunol. 2, 283-291 (2002).
43. Yewdell JW, Bennink JR. Immunodominance in major histocompatibility complex class I-restricted T-lymphocyte responses. Ann. Rev. Immunol. 17, 51-88 (1999).
44. Wilson CC, McKinney D, Anders M et al. Development of a DNA vaccine designed to induce cytotoxic T-lymphocyte responses to Multiple conserved epitopes in HIV-1. J. Immunol. 171, 5611-5623 (2003).
45. Gallimore A, Dumrese T, Hengartner H, Zinkernagel RM, Rammensee HG. Protective immunity does not correlate with the hierarchy of virus-specific cytotoxic T-cell responses to naturally processed peptides. J. Exp. Med. 187, 1647-1657 (1998).
46. Korber B, Gaschen B, Yusim K, Thakallapally R, Kesmir C, Detours V. Evolutionary and immunological implications of contemporary HIV-1 variation. Br. Med. Bull. 58, 19-42 (2001).
47. Nkolola JP, Wee EG-T, Im E-J et al. Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa. Gene Ther. (In Press) (2004).
48. Gotch FM, Hovell R, Delchambre M, Silvera P, McMichael AJ. Cytotoxic T-cell response to simian immunodeficiency virus by cynomolgus macaque monkeys immunized with recombinant vaccinia virus. AIDS 5, 317-320 (1991).
49. Xu XN, Screaton GR, McMichael AJ. Virus infections: escape, resistance and counterattack. Immunity 15, 867-870 (2001).
50. Dunlop LR, Oehlberg KA, Reid JJ, Avci D, Rosengard AM. Variola virus immune evasion proteins. Microbes Infect. 5, 1049-1056 (2003).
51. Hammarlund E, Lewis MW, Hansen SG et al. Duration of antiviral immunity after smallpox vaccination. Nature Med. 9, 1131-1137 (2003). Dectection of vaccina virus-specific memory T-cells in individuals vaccinated against smallpox many years ago.
52. Crotty S, Felgner P, Davies H, Glidewell J, Villarreal L, Ahmed R. Cutting edge: long-term B-cell memory in humans after smallpox vaccination. J. Immunol. 171, 4969-4973 (2003). Dectection of vaccinia virus-specific memory T-cells in individuals vaccinated against smallpox many years ago.
53. Drexler I, Staib C, Kastenmuller W et al. Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T-cells and comparative analysis of smallpox vaccines. Proc. Natl Acad. Sci. USA 100, 217-222 (2003).
54. Seth A, Ourmanov I, Schmitz JE et al. Immunization with a modified vaccinia virus expressing simian immunodeficiency virus (SIV) Gag-Pol primes for an anamnestic Gag-specific cytotoxic T-lymphocyte response and is associated with reduction of viremia after SIV challenge. J. Virol. 74, 2502-2509 (2000).
55. Sette A, Vitiello A, Reherman B et al. The relationship between class I binding affinity and immunogenicity of potential cytotoxic T-cell epitopes. J. Immunol. 153, 5586-5592 (1995).
56. Hanke T, Neumann VC, Blanchard TJ et al. Effective induction of HIV-specific CTL by multi-epitope DNA using a gene gun in a combined vaccination regime. Vaccine 17, 589-596 (1999).
57. Ourmanov I, Bilska M, Hirsch VM, Montefiori DC. Recombinant modified vaccinia virus ankara expressing the surface gp120 of simian immunodeficiency virus (SIV) primes for a rapid neutralizing antibody response to SIV infection in macaques. J. Virol. 74, 2960-2965 (2000).
58. Ourmanov I, Brown CR, Moss B et al. Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV. J. Virol. 74, 2740-2751 (2000).
59. Sharpe S, Polyanskaya N, Dennis M et al. Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: influence of pre-existing antivector immunity. J. Gen. Virol. 82, 2215-2223 (2001).
60. Sutter G, Wyatt LS, Foley PL, Bennink JR, Moss B. A recombinant vector derived from the host range-restricted and highly attenuated MVA strain of vaccinia virus stimulates protective immunity in mice to influenza virus. Vaccine 12, 1032-1040 (1994).
61. Bender BS, Rowe CA, Taylor SF, Wyatt LS, Moss B, Small PAJ. Oral immunization with a replication-deficient recombinant vaccinia virus protects mice against influenza. J. Virol. 70, 6418-6424 (1996).
62. Durbin AP, Wyatt LS, Siew J, Moss B, Murphy BR. The immunogenicity and efficacy of intranasally or parenterally administered replication-deficient vaccinia-parainfluenza virus Type 3 recombinants in rhesus monkeys. Vaccine 16, 1324-1330 (1998).
63. Belyakov IM, Wyatt LS, Ahlers JD et al. Induction of a mucosal cytotoxic T-lymphocyte response by intrarectal immunization with a replication-deficient recombinant vaccinia virus expressing human immunodeficiency virus 89.6 envelope protein. J. Virol. 71, 8264-8272 (1998).
64. Belyakov IM, Moss B, Strober W, Berzofsky JA. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by pre-existing poxvirus immunity. Proc. Natl Acad. Sci. USA 96, 4512-4517 (2000).
65. Trevor KT, Hersh EM, Brailey J, Balloul JM, Acres B. Transduction of human dendritic cells with a recombinant modified vaccinia Ankara virus encoding MUC1 and IL-2. Cancer Immunol. Immunother. 50, 397-407 (2001).
66. Hodge JW, Sabzevari H, Yafal AG, Gritz L, Lorenz MG, Schlom J. A triad of costimulatory molecules synergize to amplify T-cell activation. Cancer Res. 59, 5800-5807 (1999). Synergistic enhancement of MVA immunogenicity by coinsertion of costimulatory and adhesion surface molecules.
67. Paul S, Regulier E, Rooke R et al. Tumor gene therapy by MVA-mediated expression of T-cell-stimulating antibodies. Cancer Gene Ther. 9, 470-477 (2002).
68. Hanke T, Blanchard TJ, Schneider J et al. Enhancement of MHC class I-restricted peptide-specific T-cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 16, 439-445 (1998). The first demonstration of effective induction of CTLs by DNA prime-MVA boost regimen.
69. + T-cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nature Med. 4, 397-402 (1998). The first demonstration of effective induction of protective T-cell responses by DNA prime-MVA boost regimen, which were superior to those induced by each vector alone.
70. Hanke T, Samuel RV, Blanchard TJ et al. Effective induction of simian immunodeficiency virus-specific cytotoxic T-lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J. Virol. 73, 7524-7532 (1999). The first demonstration of effective induction of CTLs by DNA prime-MVA boost regimen in nonhuman primates.
71. Allen TM, Vogel TU, Fuller DH et al. Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J. Immunol. 164, 4968-4978 (2000).
72. Amara RR, Villinger F, Altman JD et al. Control of a mucosal challenge and prevention of AIDS by a multi-protein DNA/MVA vaccine. Science 292, 69-74 (2001). Demonstration of a partial protective efficacy of DNA prime-MVA boost protocol against SHIV challenge in macaques.
73. Shiver JW, Fu TM, Chen L et al. Replication-incompetent adenoviral vaccine vector elicits effective antiimmunodeficiency-virus immunity. Nature 415, 331-335 (2002).
74. Gilbert SC, Schneider J, Hannan CM et al. Enhanced CD8 T-cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine 20, 1039-1045 (2002).
75. + T-cell response in mice against an HIV-1 epitope than DNA-Poxvirus prime-booster approach. Biotechnol. Appl. Biochem. (2003).
76. Prieur E, Gilbert SC, Schneider J et al. A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses. Proc. Natl Acad. Sci. USA 101, 290-295 (2004).
77. Hanke T, Barnfield C, Wee EG-T et al. Construction and immunogenicity in a prime-boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine. J. Gen. Virol. 84, 361-368 (2003).
78. Nilsson C, Makitalo B, Berglund P et al. Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus Ankara. Vaccine 19, 3526-3536 (2001).
79. Gherardi MM, Najera JL, Perez-Jimenez E, Guerra S, Garcia-Sastre A, Esteban M. Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes. J. Virol. 77, 7048-7057 (2003).
80. Hanke T, McMichael AJ. Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nature Med. 6, 951-955 (2000).
81. Appay V, Dunbar PR, Callan M et al. Memory CD8+ T-cells vary in differentiation phenotype in different persistent virus infections. Nature Med. 8, 379-385 (2002).